Numbers
Figures converted from INR at historical FX rates — see fx_rates.json for the rate table. Ratios, margins, and multiples are unitless and unchanged.
Key market‑based metrics — current share price, market capitalisation, Quality Score, Fair Value, and historical valuation multiples — were unavailable in the source data. The following analysis is grounded solely in the audited financial statements. Any investment conclusion should incorporate the missing market data.
Snapshot
Revenue ($M)
Net Profit ($M)
Operating Margin
Total Assets ($M)
EPS ($)
FY2025, as per reported financials, converted to USD at period‑end rates.
Revenue & Earnings Power — 20-Year View
Revenue scale swings dramatically — from $11.4 billion in FY21 to $2.8 billion in FY20 — reflecting the lumpy nature of group premium flows. Operating income turned positive again only in FY25 after a prolonged stretch of technical losses.
Operating margin has spent most of the last decade near zero or negative; net margin has stabilised around 2–4% only in the most recent years. The business model runs on thin spreads at the profit-after-tax level.
Quarterly revenue volatility remains extreme — the Q3‑FY25 collapse followed by a spike in Q3‑FY26 shows how much group‑business timing can distort the top line. The metric the market watches is individual adjusted FYP, which is not available in this dataset.
Cash Generation — Are the Earnings Real?
Cash‑from‑operations has been deeply negative in the last two reported years (‑$1,101M in FY25). This is typical for a growing life insurer, but the gap between reported profit and cash receipts is a warning signal that should be reconciled with solvency‑margin disclosures.
Over the last five fiscal years, the ratio of free cash flow to net income has fluctuated enormously — swinging from strongly positive to deeply negative as the business cycle dominates. The trailing average is well outside the 80–120% band that characterises straightforward conversions.
Capital Allocation
Detailed breakdown of dividends, buybacks, acquisitions, and SBC is not available from the current dataset. The aggregate financing cash flow is used as a high‑level indicator.
The company’s financing flows are modest relative to its balance sheet. Absent a detailed capital‑allocation dataset, it is not possible to judge the discipline around dividends, buybacks, or M&A.
Balance Sheet Health
The insurer has historically carried negligible leverage. A sub‑debt issuance pushed the ratio to ~0.12 in FY25, still a conservative level. Altman‑Z score is not computable from the available dataset.
Valuation — Now vs Its Own History
Price data and historical valuation multiples are unavailable. This section cannot be produced.
Peer Comparison
ICICI Prudential’s own market cap and P/E are unavailable. The table shows that it competes with companies trading at a wide P/E dispersion, largely a function of growth expectations and distribution access.
Fair Value & Scenario
Without a Fair Value estimate from the source data, a formal valuation range cannot be constructed. Investors should overlay a target multiple derived from the peer table against ICICI Prudential’s own ROE trajectory and distribution‑mix outlook to form a view.
Closing
The numbers confirm that ICICI Prudential operates a thin‑margin life insurance model, where reported profits mask huge cash‑flow swings driven by premium‑growth cycles. What the data contradicts is the idea that earnings are steadily compounding — the pattern is one of recovery from a deep trough rather than secular growth. The single metric to watch is individual adjusted first‑year premium (not available in this set), because it is the lead indicator that will either cement the FY25 profit recovery or show it to be another false start.